25.7% Return Seen to Date on SmarTrend Misonix Call (MSON)
Comtex SmarTrend(R) - 2 hrs 7 mins ago
SmarTrend identified an Uptrend for Misonix (NASDAQ:MSON) on November 26th, 2013 at $5.34. In approximately 6 months, Misonix has returned 25.66% as of today's recent price of $6.71.
Misonix, Inc. Announces Third Quarter Fiscal Year 2014 Financial Results
PR Newswire - Thu May 08, 3:01PM CDT
Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced financial results for the third quarter of fiscal year 2014 and nine months ended March 31, 2014.
Misonix Has Returned 12.4% Since SmarTrend Recommendation (MSON)
Comtex SmarTrend(R) - Tue May 06, 11:19AM CDT
SmarTrend identified an Uptrend for Misonix (NASDAQ:MSON) on November 26th, 2013 at $5.34. In approximately 5 months, Misonix has returned 12.38% as of today's recent price of $6.00.
Misonix, Inc. To Report Third Quarter 2014 Financial Results On Thursday, May 8, 2014
PR Newswire - Fri May 02, 12:36PM CDT
Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced today that it will report financial results for the third quarter of fiscal year 2014 on Thursday, May 8, 2014. The Company has scheduled a conference call that same day, Thursday, May 8, 2014, at 4:30 pm ET to review the results.
Uptrend Call Working As Misonix Stock Rises 12.4% (MSON)
Comtex SmarTrend(R) - Tue Apr 29, 10:04AM CDT
SmarTrend identified an Uptrend for Misonix (NASDAQ:MSON) on November 26th, 2013 at $5.34. In approximately 5 months, Misonix has returned 12.36% as of today's recent price of $6.00.
Misonix Up 5.2% Since SmarTrend Uptrend Call (MSON)
Comtex SmarTrend(R) - Tue Apr 15, 9:28AM CDT
SmarTrend identified an Uptrend for Misonix (NASDAQ:MSON) on November 26th, 2013 at $5.34. In approximately 5 months, Misonix has returned 5.24% as of today's recent price of $5.62.
Misonix Up 24.7% Since SmarTrend Uptrend Call (MSON)
Comtex SmarTrend(R) - Mon Mar 24, 11:05AM CDT
SmarTrend identified an Uptrend for Misonix (NASDAQ:MSON) on November 26th, 2013 at $5.34. In approximately 4 months, Misonix has returned 24.72% as of today's recent price of $6.66.
Misonix Shares Up 26.8% Since SmarTrend's Buy Recommendation (MSON)
Comtex SmarTrend(R) - Mon Mar 17, 9:42AM CDT
SmarTrend identified an Uptrend for Misonix (NASDAQ:MSON) on November 26th, 2013 at $5.34. In approximately 4 months, Misonix has returned 26.78% as of today's recent price of $6.77.
Wound Debridement Products - Global Strategic Business Report
M2 - Wed Mar 12, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffjwkx/wound_debridement) has announced the addition of the "Wound Debridement Products - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Wound Debridement Products in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - Advanced Medical Solutions Group plc - ArthroCare Corporation - Coloplast A/S - Derma Sciences, Inc. - Misonix, Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends And Issues 3. Product Overview 4. Strategic Corporate Developments 5. Focus On Select Global Players 6. Global Market Perspective III. Competitive Landscape For more information visit http://www.researchandmarkets.com/research/ff...ebridement About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Ablation Technologies Market 2012-2016: Major Cancer Diseases that Use Ablation Technology Devices are Discussed in Detail
M2 - Mon Mar 10, 11:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5z78kx/global_ablation) has announced the addition of the "Global Ablation Technologies Market 2012-2016" report to their offering. The analysts forecast the Global Ablation Technologies market to grow at a CAGR of 10.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased demand for minimally invasive surgical procedures. The Global Ablation Technologies market has also been witnessing the trend of miniaturizing medical devices. However, the varying regulations for medical devices could pose a challenge to the growth of this market. Ablation technology devices are used for various clinical applications and Cancer therapy, and accounted for the largest segment of the Global Ablation Technologies market. The key vendors dominating this market space include Boston Scientific Corp., Medtronic Inc., St.Jude Medical Inc., and Varian Medical Systems Inc. The other vendors mentioned in the report are Accuray Inc., Alcon Laboratories Inc., AngioDynamics Inc., Arthrocare Corp., Atricure Inc., ATS Medical Inc., Biosense Webster Inc., BSD Medical Corporation, C.R. Bard Inc., Candela Corp., CardioGenesis Corp., CermaVEIN SAS, ConMed Corporation, Covidien plc, EDAP TMS S.A., Elekta AB, Endo Health Solutions Inc., Galil Medical Ltd., HealthTronics Inc., Hologic Inc., Idoman Ltd., Maquet Holding GmbH and Co. KG (Gentinge AB group), Microsulis Medical Ltd, Misonix Inc., nContact Surgical Inc., Olympus Corp., Relievant Medsystems, Rhythmia Medical Inc., Smith and Nephew plc, Solta Medical Inc., Syneron Medical Ltd., TheraGenics Corp., Urologix Inc., VNUS Medical Technologies Inc., and Zeltiq Aesthetics Inc. Commenting on the report, an analyst from the Healthcare team said: One of the upcoming trends in the Global Ablation Technology market is the rapid advancements in technology using ablation technology devices. Although the market for ablation technology devices is at a mature stage, the level of technology is still at a nascent stage; more devices with cutting-edge technology are expected to be introduced in the near future. Recently, laser ablation devices have been introduced to perform precise ablation of body tissue; these devices run on a laser energy transmission mechanism using fiber optics. This kind of device is used in transmyocardial revascularization and angioplasty. Another major advancement is the usage of catheter ablation for atrial fibrillation, which is commonly used to control tachy-arrhythmia. Thus, the rapid advancement in technology is an emerging trend that has a strong impact on the market. For more information visit http://www.researchandmarkets.com/research/5z...l_ablation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Misonix Exhibits At The 65th Southern Neurosurgical Society Annual Conference And Offers Extensive "Hands-On" BoneScalpel(TM) and SonaStar® Product Demonstrations
PR Newswire - Thu Mar 06, 1:47PM CST
Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, recently attended the 65th Southern Neurosurgical Society (SNS) Annual Meeting in San Juan, Puerto Rico from February 19-22, 2014.
Misonix Reports More Than 200 Podiatry Professionals Trial the SonicOne® O.R.
PR Newswire - Mon Mar 03, 1:18PM CST
Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, recently attended the 72nd Annual Scientific Conference of the American College of Foot and Ankle Surgeons where more than 200 podiatric professionals engaged in "hands-on" trials of Misonix's SonicOne O.R. Ultrasonic Surgical Debridement System. The conference took place at the Gaylord Palms Convention Center in Kissimmee, Florida from February 27, through March 1, 2014.
A MICHAEL. MCMANUS JR of Misonix Inc. (MSON)-NasdaqGM bought Shares of MSON
M2 - Mon Feb 24, 8:17AM CST
Reported by InsiderCow.com at 2014-02-21 14:08:57
Shares of MSON Up 22.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 14, 9:44AM CST
SmarTrend identified an Uptrend for Misonix (NASDAQ:MSON) on November 26th, 2013 at $5.34. In approximately 3 months, Misonix has returned 22.85% as of today's recent price of $6.56.